James Crowe Jr. Archives
VUMC-led team ‘sprints’ to develop Zika virus treatment
Apr. 11, 2019—In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.
VUMC joins effort to stop spread of two deadly viruses
Mar. 25, 2019—Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.
VUMC chikungunya antibody set to enter clinical trial
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Researchers push forward frontiers of vaccine science
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Designing antibodies to fight the flu
Jan. 31, 2019—Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.
VUMC scientists ‘sprint’ to find anti-Zika antibodies
Jan. 24, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Discovery could lead to neutralizing West Nile virus
Dec. 6, 2018—Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.
Translational Research Forum set for Oct. 26
Oct. 18, 2018—Patricia Griffin, MD, chief of the Enteric Diseases Epidemiology Branch at the U.S. Centers for Disease Control and Prevention (CDC), will be the guest speaker at the 2018 Vanderbilt Translational Research Forum Oc. 26 at the Vanderbilt Student Life Center.
Symposium to focus on prospects for a universal flu vaccine
Oct. 11, 2018—Internationally known vaccine experts including Vanderbilt University’s James Crowe Jr., MD, will speak next month at a symposium in Nashville on prospects for a universal flu vaccine.
Team isolates antibodies that neutralize GI bug norovirus
Aug. 30, 2018—Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.
Team finds potent antibodies against three Ebola viruses
Jul. 19, 2018—Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.
New target to stop Ebola
May. 21, 2018—A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.
